0HB0.LAgios Pharmaceuticals, Inc.

Acerca de

Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

www.agios.com

Estadísticas clave

Cap. de mercado

2.22B

BPA

-7.12

Rend. dividendo

0.00%

Beta

0.59

P/VC

1.32

ROE

-34.6%

Sector

Healthcare

Industria

Biotechnology

CEO

Brian Goff

Empleados

486

Fecha IPO

2018-01-29

País

US